CDKN2A and osteosarcoma: Different degrees of abnormalities in the CDKN2A/MDM2/p53/RB1/E2F1 signalling may correlate with the peculiar response to the drug combination that we observed in the seven osteosarcoma cell lines (induction of apoptosis/inhibition of proliferation).